Table 3.

Immune Therapies Using Allogeneic Cells or Tissue

Site/Investigator	Description	Disease	Study Phase - Enrollment	References
City of Hope, Duarte, CA/B Badie	Allogeneic T Cells modified with chimeric IL-13α2 - TCRζ	brain tumor	I - 10	97
Penn State Univ, Hershey, PA/ K Lucas	Allogeneic, CMV specific CTL	brain tumor	I/II - 10	98
UCLA, Los Angeles, CA/L Liau & C Kruse	Alloreactive CTL and IL-2	brain tumor	I - 15	93, 99
NovaRx, San Diego, CA/H Fakhrai	Allogeneic Tumor Cell Vaccine with TGF 2 knockdown	non-small cell lung carcinoma and brain tumor	II -75	100
Baylor, Houston, TX/J Fay	Autologous DC pulsed with Allogeneic Melanoma Tumor	melanoma	I/II - 33	Clinicaltrials.gov, NCT00313235
IDM Res Lab, Sanofi-Aventis, Paris, France/M Salcedo	Autologous DC pulsed with Allogeneic Melanoma Tumor	melanoma	I/II - 15	101
Univ Pittsburgh, Pittsburgh, PA/ G Chatta	Autologous DC pulsed with Allogeneic Prostate Tumor	prostate cancer	I - 12	Clinicaltrials.gov, NCT00970203